DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 4 filers reported holding DENALI THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $508,096 | -36.4% | 24,629 | -9.0% | 0.03% | -33.3% |
| Q2 2023 | $798,511 | +29.3% | 27,059 | +1.0% | 0.04% | +25.8% |
| Q1 2023 | $617,449 | -11.6% | 26,799 | +6.7% | 0.03% | -16.2% |
| Q4 2022 | $698,476 | +11.6% | 25,116 | +23.1% | 0.04% | +5.7% |
| Q3 2022 | $626,000 | +59.3% | 20,397 | +52.8% | 0.04% | +75.0% |
| Q2 2022 | $393,000 | +8.3% | 13,350 | +18.2% | 0.02% | +17.6% |
| Q1 2022 | $363,000 | -15.6% | 11,296 | +17.2% | 0.02% | -10.5% |
| Q4 2021 | $430,000 | -8.5% | 9,638 | +3.5% | 0.02% | -9.5% |
| Q3 2021 | $470,000 | – | 9,312 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 5,960,732 | $122,969,901 | 14.32% |
| ARCH Venture Management, LLC | 693,749 | $14,312,042 | 9.30% |
| Flagship Pioneering Inc. | 2,619,968 | $54,049,940 | 3.92% |
| Casdin Capital, LLC | 1,300,000 | $26,819,000 | 2.97% |
| Yiheng Capital Management, L.P. | 1,150,684 | $23,738,611 | 1.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 154,000 | $3,172,400 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 254,941 | $5,259,433 | 1.02% |
| Temasek Holdings (Private) Ltd | 6,895,992 | $142,264,315 | 0.85% |
| Clarius Group, LLC | 378,262 | $7,803,545 | 0.74% |
| Artal Group S.A. | 802,899 | $16,564 | 0.71% |